Canagliflozin Beneficial Even for Advanced Kidney Disease
MONDAY, Nov. 30, 2020 -- Treatment with the sodium glucose cotransporter 2 (SGLT2) inhibitor canagliflozin reduces the rate of kidney disease progression among participants with an estimated glomerular filtration rate (eGRF)<30 mL/min/1.73 m2,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Canagliflozin | Invokana | Pharmaceuticals | SGLT2 Inhibitors | Sodium | Urology & Nephrology